PharmaVOICE Blog Post

FLU-PRO©: InFLUenza Patient-Reported Outcome

Posted By: Dan Limbach
April 27, 2020

Access the on-demand webinar now

The FLU-PRO is a self-administered patient-reported outcome measure (PRO) to quantify symptom severity in influenza and influenza-like illness. The instrument was developed by a team of academic investigators spanning multiple sites across many countries under the direction of Dr. John H. Powers of George Washington University and the University of Maryland and with the assistance of Evidera’s Patient-Centered Research staff. Copyright, licensing, and oversight of the FLU-PRO are managed by Leidos Biomedical Research. Information on the FLU-PRO is provided as a public service.


  • It was developed using qualitative and quantitative methods consistent with scientific measurement standards and US Food and Drug Administration (FDA) and European Medicines Agency (EMA) guidelines for clinical outcome assessments
  • It has been tested and used in studies of influenza, influenza-like illness (ILI), respiratory syncytial virus (RSV), rhinovirus, and enterovirus
  • To date, the FLU-PRO has been completed by over 4,000 patients between 12-81 years of age with adherence rates over 90%
  • The FLU-PRO is a 32-item instrument that assesses severity of symptoms of influenza and influenza-like illness across six body systems: Nose, Throat, Eyes, Chest/Respiratory, Gastrointestinal, and Body/Systemic

This webinar covers:

  • Methods used to develop the FLU-PRO and its suitability for evaluating symptoms in clinical trials of COVID-19
  • Insight into the type of research questions FLU-PRO can help address
  • The benefits and potential challenges of use in COVID studies
  • Information on how to access and license the instrument

Watch the webinar now

About the Blog Poster: Dan Limbach

Comments are closed.